Compare DTI & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTI | IMA |
|---|---|---|
| Founded | 1984 | 2019 |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.0M | 66.3M |
| IPO Year | 2021 | N/A |
| Metric | DTI | IMA |
|---|---|---|
| Price | $2.31 | $5.59 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 315.1K | 8.4K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $154,446,000.00 | N/A |
| Revenue This Year | $2.05 | N/A |
| Revenue Next Year | $4.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.59 | N/A |
| 52 Week Low | $1.65 | $3.94 |
| 52 Week High | $4.69 | $17.50 |
| Indicator | DTI | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 52.20 | 43.53 |
| Support Level | $2.29 | $5.36 |
| Resistance Level | $2.34 | $6.13 |
| Average True Range (ATR) | 0.08 | 0.31 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 88.71 | 22.45 |
Drilling Tools International Corp is an oilfield services company that designs, engineers, and manufactures rental-focused tools used in onshore and offshore horizontal and directional drilling operations, as well as solutions across the well life cycle. It operates through two geographic segments: Western Hemisphere and Eastern Hemisphere. The Western Hemisphere, which generates the majority of revenue, provides downhole drilling tools and rental services for onshore and offshore operations across North America and Latin America, supported by service centers in the U.S. and Canada. The Eastern Hemisphere covers Europe, the Middle East, and Asia-Pacific, where the company offers drilling and well lifecycle solutions through international service centers across the EMEA and APAC regions.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.